{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:35:52Z","timestamp":1792708552602,"version":"4.5.0"},"reference-count":57,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The antifungal efficacy, pharmacokinetics, and safety of caspofungin (CAS) were investigated in the treatment and prophylaxis of invasive pulmonary aspergillosis due to\n            <jats:italic>Aspergillus fumigatus<\/jats:italic>\n            in persistently neutropenic rabbits. Antifungal therapy consisted of 1, 3, or 6 mg of CAS\/kg of body weight\/day (CAS1, CAS3, and CAS6, respectively) or 1 mg of deoxycholate amphotericin B (AMB)\/kg\/day intravenously for 12 days starting 24 h after endotracheal inoculation. Prophylaxis (CAS1) was initiated 4 days before endotracheal inoculation. Rabbits treated with CAS had significant improvement in survival and reduction in organism-mediated pulmonary injury (OMPI) measured by pulmonary infarct score and total lung weight (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01). However, animals treated with CAS demonstrated a paradoxical trend toward increased residual fungal burden (log CFU per gram) and increased serum galactomannan antigen index (GMI) despite improved survival. Rabbits receiving prophylactic CAS1 also showed significant improvement in survival and reduction in OMPI (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01), but there was no effect on residual fungal burden. In vitro tetrazolium salt hyphal damage assays and histologic studies demonstrated that CAS had concentration- and dose-dependent effects on hyphal structural integrity. In parallel with a decline in GMI, AMB significantly reduced the pulmonary tissue burden of\n            <jats:italic>A. fumigatus<\/jats:italic>\n            (\n            <jats:italic>P<\/jats:italic>\n            \u2264 0.01). The CAS1, CAS3, and CAS6 dose regimens demonstrated dose-proportional exposure and maintained drug levels in plasma above the MIC for the entire 24-h dosing interval at doses that were \u22653 mg\/kg\/day. As serial galactomannan antigen levels may be used for therapeutic monitoring, one should be aware that profoundly neutropenic patients receiving echinocandins for aspergillosis might have persistent galactomannan antigenemia despite clinical improvement. CAS improved survival, reduced pulmonary injury, and caused dose-dependent hyphal damage but with no reduction in residual fungal burden or galactomannan antigenemia in persistently neutropenic rabbits with invasive pulmonary aspergillosis.\n          <\/jats:p>","DOI":"10.1128\/aac.46.1.12-23.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"12-23","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":157,"title":["Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia"],"prefix":"10.1128","volume":"46","author":[{"given":"Ruta","family":"Petraitiene","sequence":"first","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidmantas","family":"Petraitis","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin","family":"Sein","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Schaufele","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Francesconi","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bacher","sequence":"additional","affiliation":[{"name":"Surgery Service, Veterinary Resources Program, Office of Research Services"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilo A.","family":"Avila","sequence":"additional","affiliation":[{"name":"Department of Radiology, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2333"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2310-2318.2000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_1.S43"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.327-330.2001"},{"key":"e_1_3_2_6_2","first-page":"302","volume":"18","year":"1999","unstructured":"Barchiesi, F., A. M. Schimizzi, A. W. Fothergill, G. Scalise, and M. G. Rinaldi. 1999. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis.18:302\u2013304.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2326"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.3.7663787"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jac\/43.4.491","volume":"43","year":"1999","unstructured":"Brummer, E., S. D. Chauhan, and D. A. Stevens. 1999. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. J. Antimicrob. Chemother.43:491\u2013496.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.253"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.139"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00236-4"},{"key":"e_1_3_2_13_2","first-page":"S1","volume":"14","year":"1994","unstructured":"De Bock, R. 1994. Epidemiology of invasive fungal infections in bone marrow transplantation. Bone Marrow Transplant.14(Suppl. 5):S1\u2013S2.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.48.100194.002351"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.8.1835"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.608"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/40.5.611","volume":"40","year":"1997","unstructured":"Denning, D. W. 1997. Echinocandins and pneumocandins\u2013a new antifungal class with a novel mode of action. J. Antimicrob. Chemother.40:611\u2013614.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.10.2950-2956.1998"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.35.1.139-143.1997"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.2.356"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.2.269"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(00)88890-3"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.151"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.8.1775"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1937"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.596-600.2001"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2845-2855.2001"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.1999.00496.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60129-5"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2339"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00004728-198705000-00033","volume":"11","year":"1987","unstructured":"Hruban, R. H., M. A. Meziane, E. A. Zerhouni, P. S. Wheeler, J. S. Dumler, and G. M. Hutchins. 1987. Radiologic-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis. J. Comput. Assisted Tomogr.11:534\u2013536.","journal-title":"J. Comput. Assisted Tomogr."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1957"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.157.3.3864189"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681219780000961"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1480"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.5.938"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.5.1625-1627.1999"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.10.3223-3228.1999"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00050-9"},{"key":"e_1_3_2_41_2","unstructured":"National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_42_2","unstructured":"Guide for the care and use of laboratory animals 1996"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681219780001291"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.368-377.2000"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920601)69:11<2653::AID-CNCR2820691106>3.0.CO;2-8"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200007000-00006"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00246-0"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.1985"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.2.497-500.1995"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.6.2237-2245.1992"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1612"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.7.1912-1914.1995"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.25.5.931-932.1987"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70303-2"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1065"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/mmy.38.s1.335.347"},{"key":"e_1_3_2_57_2","first-page":"467","volume":"38","year":"1988","unstructured":"Walsh, T. J., J. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Sci.38:467\u2013471.","journal-title":"Lab. Anim. Sci."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01117450"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.1.12-23.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.1.12-23.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:30:56Z","timestamp":1645464656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.1.12-23.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1128\/AAC.46.1.12-23.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.1.12-23.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]},"assertion":[{"value":"2001-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}